@article{d4b7daab628a47808bc89b23c3c07564,
title = "18F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases",
abstract = "Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy. In a first-in-human dose escalation trial of bone targeted Radium 223 dichloride alpha-particle therapy in 18 patients with advanced osteosarcoma only 1 patient responded based on conventional Response Evaluation Criteria in Solid Tumors (RECIST). Na18F PET response Criteria in Solid Tumors(NAFCIST), based on Sodium fluoride-18 (Na18F) positron emission tomography (PET)-CT was developed to better evaluate bone specific response. To further appreciate the spatial and temporal heterogeneity of the partial or mixed responses, a radiomics method was developed. Analyses were performed with 18F-sodium fluoride positron emission tomography imaging studies before and after alpha-particle therapy. Radioactive 18F− -atom concentrations were measured in soft-tissues, in approximately 1000 concentration data points for 18F− per 1 cm3 metastatic tumor. Data was analyzed from the SUV intensity values, the histogram of intensities and entropy values. Radiomics may inform intra-tumoral and inter-tumoral heterogeneity in response of bone forming osteosarcoma to alpha particle therapy. Each patient (and each tumor) represents an “N of 1” case and warrants in depth analysis individually.",
keywords = "Alpha therapy, Entropy, Fluorine-18 isotopes, Osteosarcoma, Positron emission tomography, Radiomics, Radium-223 isotopes, Sodium fluoride PET",
author = "Kalevi Kairemo and Jason Roszik and Pete Anderson and Gregory Ravizzini and Arvind Rao and Macapinlac, {Homer A.} and Vivek Subbiah",
note = "Funding Information: Funding was provided by the Shannon Wilkes Osteosarcoma Research Foundation , the High-Impact Clinical Research Support at The University of Texas MD Anderson Cancer Center , and the National Institutes of Health Cancer Center Support Grants CA016672, CA046592 as well as RSG-16-005-01 from the American Cancer Society . Funding Information: Funding was provided by the Shannon Wilkes Osteosarcoma Research Foundation, the High-Impact Clinical Research Support at The University of Texas MD Anderson Cancer Center, and the National Institutes of Health Cancer Center Support Grants CA016672, CA046592 as well as RSG-16-005-01 from the American Cancer Society. Conflicts of interest: AR is a member of Voxel Analytics, LLC and has received funding from Agilent Technologies. VS reports Research funding/ Grant support for clinical trials: Novartis, Bayer,Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint medicines, Loxo oncology, Medimmune, Altum, Dragonfly therapeutics, Takeda and, National Comprehensive Cancer Network, NCI-CTEP and UT MD Anderson Cancer Center, Turning point therapeutics, Boston Pharmaceuticals Travel funding: Novartis, Pharmamar, ASCO, ESMO, Helsinn, Incyte, Ad Hoc Advisory board: Helsinn, LOXO Oncology/ Eli Lilly, R-Pharma US, INCYTE, QED pharma, Medimmune, Novartis, Signant Health. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = oct,
doi = "10.1016/j.currproblcancer.2021.100797",
language = "English (US)",
volume = "45",
journal = "Current Problems in Cancer",
issn = "0147-0272",
publisher = "Mosby Inc.",
number = "5",
}